Midenin Malign Neoplazmının Neden Olduğu Ölümlerin Sağlıklı Yaşam Beklentisi (SYB) ile İlişkisi: ICD-10 Mortalite Listesinde Zamana Dayalı Bir Boylamsal Analiz

Öz

Amaç: Bu araştırmada, midenin malign neoplazmına bağlı ölümlerin sağlıklı yaşam beklentisi (SYB) ile ilişkisinin değerlendirilmesi amaçlandı. Yöntem: 1996-2017 yılları arasında 14 ülke için Dünya Sağlık Örgütü (DSÖ) tarafından yayınlanan ICD-10 ölüm verileri ile yine DSÖ tarafından yayınlanan SYB-doğum ve SYB-60 yaş parametreleri kullanıldı. Araştırma parametrelerinin analizinde Spearman’ın rho yıl kontrollü kısmi korelasyon analizi ve Logit modeli kullanıldı. Bulgular: Tüm yıllar ve ülkeler için minimum toplam ölüm 1, maksimum ölüm 25.898 idi. Ortalama ölüm 3.030.50±6.307.23 idi. SYB-doğum ortalaması 62.75±4.52, SYB-60 yaş ortalaması 13.93±1.90 idi. Hem Spearman'ın rho korelasyon analizi hem de yıl kontrollü kısmi korelasyon analizi sonuçları, mide malign neoplazmına bağlı ölümün SYB-doğum ve SYB-60 yaş ile negatif korelasyon gösterdiğini gösterdi (p<0.01). Yıl kontrollü korelasyon katsayıları, bu korelasyonların zaman diliminde azalma eğiliminde olduğunu gösterdi. Hem SYB-doğum hem de SYB-60 yaş midenin malign neoplazmından, cinsiyet ve ülkeden önemli ölçüde etkilenmiştir. Yıl, SYB-60 yaş üzerinde pozitif ve anlamlı bir etkiye sahipken (p<0.01), SYB-doğum için etkisi önemsizdi (p>0.05). Model R2 değerleri, SYB-60 yaş modelinin SYB-doğum modeline göre daha yüksek anlama sahip olduğunu göstermiştir. Sonuç: Midenin malign neoplazmına bağlı ölümler dünyanın bazı bölgelerinde hala önemli bir halk sağlığı sorunu olarak karşımıza çıkmaktadır. Ayrıca SYB-doğum ve SYB-60 yaş göstergelerinin bu ülkelerde belirli bir düzene uymaması ve zamanla bu süreçte gelişme olmaması halk sağlığı konusunda halen önemli eksikliklerin olduğunu göstermektedir. Bu tür çalışmalarla halk sağlığı değişkenlerinin küresel anlamda incelenmesi, sağlık hizmetlerinin tüm kesimlerine ulaşması ve her bireye sağlık hizmeti sunulması açısından önemlidir.

Anahtar Kelimeler

• Malign neoplazm
• Mide
• ICD-10
• Mortalite
• HALE

Relationship of deaths caused by malignant neoplasm of stomach with healthy life expectancy (HALE) : a time-based longitudinal analysis on the ICD-10 mortality list

Öz

Aim: In this research, it was aimed to evaluate relationship of deaths caused by malignant neoplasm of stomach with healthy life expectancy (HALE) : a time-based longitudinal analysis on the ICD-10 mortality list. Material and Method: World Health Organization (WHO) ICD-10 mortality data and WHO-HALE at birth and HALE at 60 ages for 14 countries between 1996-2017 were used. Spearman’s rho, year controlled partial correlation analysis and Logit model was used for analysis of research parameters. Results: Minimum total death was 1, and maximum was 25.898 for all years and countries. The mean death was 3.030.50±6.307.23. HALE at birth mean was 62.75±4.52, and HALE at 60 age mean was 13.93±1.90. Both Spearman’s rho correlation analysis and year controlled partial correlation analysis results showed that malignant neoplasm of stomach death is negatively correlated with HALE at birth and HALE at 60 ages (p<0.01). Year controlled correlation coefficients showed that these correlations have been in decreasing trend in time period. Both HALE at birth and HALE at 60 ages have significantly affected from malignant neoplasm of stomach deaths, gender and country. Year has positive and significant effect on HALE at 60 ages (p<0.01), whereas its effect was insignificant for HALE at birth (p>0.05). Model R2 values showed that HALE at 60 age model has higher explanation value than the model for HALE at birth. Conclusion: Deaths due to malignant neoplasm of stomach still emerge as an important public health problem in certain parts of the world. In addition, the fact that the HALE at birth and HALE at 60 age indicators do not have a certain order in these countries and there is no progress in time show that there are still important deficiencies in public health. With such studies, it is important to examine public health variables in the global sense in terms of reaching all segments of health services and providing health services to each individual.

Anahtar Kelimeler

• Malignant neoplasm
• Stomach
• ICD-10
• Mortality
• HALE

Kaynakça

1. 1. Samaras VD, Foukas PG, Triantafyllou K, et al. Synchronous well differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: a case report. BMC Gastroenterol. 2011;11:27. Published 2011 Mar 24. doi:10.1186/1471-230X-11-27
2. 2. Karthikeyan VS, Sistla SC, Srinivasan R, et al. Metachronous multiple primary malignant neoplasms of the stomach and the breast: report of two cases with review of literature. Int Surg. 2014;99(1):52-55. doi:10.9738/INTSURG-D-13-00056.1
3. 3. Kim YI, Koo MY. Synchronous adenocarcinoma and mantle cell lymphoma of the stomach. Yonsei Med J. 2007;48(6):1061-1065. doi:10.3349/ymj.2007.48.6.1061
4. 4. Yu J, Fu B, Zhao Q. Family history of malignant neoplasm and its relation with clinicopathologic features of gastric cancer patients. World J Surg Oncol. 2013;11(1):201. Published 2013 Aug 16. doi:10.1186/1477-7819-11-201
5. 5. Liu X, Shao L, Liu X, et al. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine. 2019;40:336-348. doi:10.1016/j.ebiom.2018.12.034
6. 6. Park SH, Kim MJ, Kwon J, et al. Solitary fibrous tumor arising from stomach: CT findings. Yonsei Med J. 2007;48(6):1056-1060. doi:10.3349/ymj.2007.48.6.1056
7. 7. Wu ZJ, Lin Y, Xiao J, Wu LC, Liu JG. Clinical significance of colonoscopy in patients with upper gastrointestinal polyps and neoplasms: a meta-analysis. PLoS One. 2014;9(3):e91810. Published 2014 Mar 17. doi:10.1371/journal.pone.0091810
8. 8. Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut. 2015;64(10):1650-1668. doi:10.1136/gutjnl-2014-307595

9. 9. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]. Lancet. 2018;392(10159):1859-1922. doi:10.1016/S0140-6736(18)32335-3
10. 10. Zaninotto P, Head J, Steptoe A. Behavioural risk factors and healthy life expectancy: evidence from two longitudinal studies of ageing in England and the US. Sci Rep. 2020;10(1):6955. Published 2020 Apr 24. doi:10.1038/s41598-020-63843-6
11. 11. GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1160-1203. doi:10.1016/S0140-6736(20)30977-6
12. 12. Cao X, Hou Y, Zhang X, et al. A comparative, correlate analysis and projection of global and regional life expectancy, healthy life expectancy, and their GAP: 1995-2025. J Glob Health. 2020;10(2):020407. doi:10.7189/jogh.10.020407
13. 13. Paciej-Gołębiowska P, Pikala M, Maniecka-Bryła I. Years of life lost due to malignant neoplasms of the digestive system in Poland in the years 2000-2014. United European Gastroenterol J. 2018;6(6):943-951. doi:10.1177/2050640618764714
14. 14. Kang HC, Menias CO, Gaballah AH, et al. Beyond the GIST: mesenchymal tumors of the stomach. Radiographics. 2013;33(6):1673-1690. doi:10.1148/rg.336135507
15. 15. Annenkov A, Nishikura K, Domori K, Ajioka Y. Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach. Virchows Arch. 2012;461(2):169-175. doi:10.1007/s00428-012-1272-5
16. 16. Terada T, Maruo H. Simultaneous large cell neuroendocrine carcinoma and adenocarcinoma of the stomach. World J Gastroenterol. 2011;17(43):4831-4834. doi:10.3748/wjg.v17.i43.4831
17. 17. Richman DM, Tirumani SH, Hornick JL, et al. Beyond gastric adenocarcinoma: Multimodality assessment of common and uncommon gastric neoplasms. Abdom Radiol (NY). 2017;42(1):124-140. doi:10.1007/s00261-016-0901-x
18. 18. Baré M, Cabrol J, Real J, et al. In-hospital mortality after stomach cancer surgery in Spain and relationship with hospital volume of interventions. BMC Public Health. 2009;9:312. Published 2009 Aug 27. doi:10.1186/1471-2458-9-312
19. 19. Kinoshita H, Hayakawa Y, Koike K. Metaplasia in the Stomach-Precursor of Gastric Cancer?. Int J Mol Sci. 2017;18(10):2063. Published 2017 Sep 27. doi:10.3390/ijms18102063
20. 20. Garg S, Mulki R, Sher D. Metastatic pancreatic cancer presenting as linitis plastica of the stomach. BMJ Case Rep. 2016;2016:bcr2015214298. Published 2016 Mar 8. doi:10.1136/bcr-2015-214298
21. 21. Wang Y, Huang CM, Wang JB, et al. Survival and surgical outcomes of cardiac cancer of the remnant stomach in comparison with primary cardiac cancer. World J Surg Oncol. 2014;12:21. Published 2014 Jan 27. doi:10.1186/1477-7819-12-21
22. 22. Ranabhat CL, Atkinson J, Park MB, Kim CB, Jakovljevic M. The Influence of Universal Health Coverage on Life Expectancy at Birth (LEAB) and Healthy Life Expectancy (HALE): A Multi-Country Cross-Sectional Study. Front Pharmacol. 2018;9:960. Published 2018 Sep 18. doi:10.3389/fphar.2018.00960
23. 23. Zheng XY, Xu XJ, Liu YY, et al. Age-standardized mortality, disability-adjusted life-years and healthy life expectancy in different cultural regions of Guangdong, China: a population-based study of 2005-2015. BMC Public Health. 2020;20(1):858. Published 2020 Jun 5. doi:10.1186/s12889-020-8420-7
24. 24. Li Y, Schoufour J, Wang DD, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ. 2020;368:l6669. Published 2020 Jan 8. doi:10.1136/bmj.l6669
25. 25. Lee JY, Ock M, Kim SH, Go DS, Kim HJ, Jo MW. Health-Adjusted Life Expectancy (HALE) in Korea: 2005-2011. J Korean Med Sci. 2016;31 Suppl 2(Suppl 2):S139-S145. doi:10.3346/jkms.2016.31.S2.S139